Webcast is Live at 7:30 a.m. (CT)
Surmodics, Inc. SRDX, a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter fiscal 2018 conference call on Friday, November 9, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release earlier that morning.
Gary Maharaj, president and chief executive officer, and Tim Arens, interim vice president of finance and chief financial officer, will recap the fourth quarter fiscal 2018 financial results and accomplishments as well as provide 2019 guidance. To access the webcast, go to the investor relations portion of the Company's website at https://surmodics.gcs-web.com the day of the conference call and click on the webcast icon.
An audio replay will be available beginning at 10:30 a.m. CT on Friday, November 9, until 10:30 a.m. CT on Friday, November 16, and can be accessed by dialing 888-203-1112 and entering conference call ID passcode 1123199. In addition, the conference call audio and transcript will be archived on the Company's website following the call.
About Surmodics, Inc.
Surmodics is the global leader in
surface modification technologies for intravascular medical devices and
a leading provider of chemical components for in vitro diagnostic
(IVD) immunoassay tests and microarrays. Surmodics is pursuing highly
differentiated whole-product solutions that are designed to address
unmet clinical needs for its medical device customers and engineered to
the most demanding requirements. This key growth strategy leverages the
combination of the Company's expertise in proprietary surface
technologies, along with enhanced device design, development and
manufacturing capabilities. The Company mission remains to improve the
detection and treatment of disease. Surmodics is headquartered in Eden
Prairie, Minnesota. For more information, visit www.surmodics.com. The
content of Surmodics' website is not part of this press release or part
of any filings that the company makes with the SEC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181030005262/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.